A Randomized, Quadruple-blinded, Placebo-controlled, Single-ascending and Multiple Dose Study to Evaluate the Safety, Local Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics, and Exploratory Clinical Activity of MY006 in Healthy Volunteers and Adolescent and Adult Patients With Peanut Allergy
Latest Information Update: 05 Jan 2026
At a glance
- Drugs MY 006 (Primary)
- Indications Peanut hypersensitivity
- Focus Adverse reactions
- Sponsors Mabylon
Most Recent Events
- 30 Dec 2025 Status changed from not yet recruiting to recruiting.
- 24 Dec 2025 New trial record